Celgene Corp., of Summit, N.J., reported fourth-quarter net product sales of $4.036 billion and total revenue of $4.037 billion. Full-year net product sales were $15.265 billion, while total revenue for 2018 was $15.281 billion. The majority of sales came from Revlimid (lenalidomide), which increased 16 percent to $2.549 billion for the fourth quarter, with $1.729 billion coming from U.S. sales. For the full year, Revlimid sales reached $9.685 billion, an increase of 18 percent year over year.